Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Amoxicillin/clavulanate | Augmentin | 4.4 Special Warnings and Special Precautions for Use , 4.8 Undesirable effects | Drug-induced enterocolitis syndrome, acute renal injury , Drug-induced enteLinear Immunoglobulin A (IgA) disease, Drug-induced enterocolitis syndrome, Pancreatitis acute | Jan,2023 |
| Fexofenadine | Telfast | 4.5. Interactions with other medicinal products, 4.8 Undesirable effects | Interactions with P-glycoprotein inhibitors or inducers, Vision blurred | Jan,2023 |
| Rifampicin | Rifadin | 4.4 Special Warnings and Special Precautions for Use , 4.5. Interactions with other medicinal products | Paradoxical drug reaction , Interactions with Clopidogrel | Mar,2023 |
| Goserelin | Zoladex | 4.8 Undesirable effects | Convulsions , suicidal ideation and attempt in women | Mar,2023 |
| Fluticasone Furoate,Umeclidinium Bromide,Vilanterol | Trelegy Ellipta | 4.8 Undesirable effects | Dysuria, urinary retention | Mar,2023 |
| Chadox1-S | R-Covi | 4.8 Undesirable effects | Cutaneous vasculitis | Mar,2023 |